文献速递肥胖与代谢综合征甲状腺疾病

瘦素降低脂肪营养不良患者能量消耗 despite 甲状腺激素升高

Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究纳入25例脂肪营养不良患者,采用非随机交叉设计,分别观察起始 metreleptin 治疗14天和撤药14天前后能量消耗等指标。结果显示起始 metreleptin 后24小时总能量消耗和静息能量消耗分别下降5.0%和5.9%,游离T3升高19.4%;撤药后游离T3和游离T4下降,但能量消耗无变化。结论提示 metreleptin 降低能量消耗,尽管甲状腺激素升高。

要点

  • 起始 metreleptin 后总能量消耗和静息能量消耗分别下降5.0%和5.9%。
  • 起始 metreleptin 后游离T3升高19.4%,撤药后游离T3和游离T4下降。
  • 撤药后能量消耗无变化,提示能量消耗改变并非单纯由甲状腺激素介导。

核心结论

  • 在脂肪营养不良患者中,起始 metreleptin 治疗降低能量消耗,但撤药后未见能量消耗变化。
  • 甲状腺激素在起始和撤药队列中均表现为 metreleptin 治疗时更高。
  • metreleptin 降低能量消耗可能源于能量需求代谢过程减少,抵消了脂肪组织特异性神经内分泌和肾上腺素能信号介导的能量消耗增加。

研究设计与样本

  • 非随机交叉研究,纳入25例脂肪营养不良患者(美国国立卫生研究院,2013-2018年)。
  • 起始队列为17例既往未暴露于 metreleptin 的患者,在治疗前和治療14天后研究。
  • 撤药队列为8例既往接受 metreleptin 治疗的患者,在撤药前和撤药14天后研究。

主要发现

  • 起始队列中,24小时总能量消耗下降5.0%(121 ± 152 kcal/day;P = 0.006),静息能量消耗下降5.9%(120 ± 175 kcal/day;P = 0.02)。
  • 起始队列中,游离T3升高19.4%(40 ± 49 pg/dL;P = 0.01),儿茶酚胺和心率变异性无变化。
  • 撤药队列中,游离T3下降8.0%(P = 0.04),游离T4下降11.9%(P = 0.002),去甲肾上腺素下降34.2%(P = 0.03),能量消耗、肾上腺素、多巴胺和心率变异性无变化。

临床怎么用

  • 对于脂肪营养不良患者,起始 metreleptin 治疗时需关注能量消耗下降及甲状腺激素升高的分离现象。
  • 撤药后甲状腺激素和去甲肾上腺素下降但能量消耗无变化,提示撤药期间能量消耗监测不能仅依赖甲状腺激素水平。

局限性

  • 研究为非随机交叉设计,样本量较小(起始队列17例,撤药队列8例)。
  • 未报告能量消耗下降的具体代谢过程机制,结论中机制解释为推测性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Leptin is an adipokine that signals energy sufficiency. In rodents, leptin deficiency decreases energy expenditure (EE), which is corrected following leptin replacement. In humans, data are mixed regarding leptin-mediated effects on EE. OBJECTIVE: To determine the effects of metreleptin on EE in patients with lipodystrophy. DESIGN, SETTING, AND PATIENTS: Nonrandomized crossover study of 25 patients with lipodystrophy (National Institutes of Health, 2013-2018). INTERVENTION: The initiation cohort consisted of 17 patients without prior exposure to metreleptin, studied before and after 14 days of metreleptin. The withdrawal cohort consisted of 8 previously metreleptin-treated patients, studied before and after 14 days of metreleptin withdrawal. MAIN OUTCOMES: 24-h total energy expenditure (TEE), resting energy expenditure (REE), autonomic nervous system activity [heart rate variability (HrV)], plasma-free triiodothyronine (T3), free thyroxine (T4), epinephrine, norepinephrine, and dopamine. RESULTS: In the initiation cohort, TEE and REE decreased by 5.0% (121 ± 152 kcal/day; P = 0.006) and 5.9% (120 ± 175 kcal/day; P = 0.02). Free T3 increased by 19.4% (40 ± 49 pg/dL; P = 0.01). No changes in catecholamines or HrV were observed. In the withdrawal cohort, free T3 decreased by 8.0% (P = 0.04), free T4 decreased by 11.9% (P = 0.002), and norepinephrine decreased by 34.2% (P = 0.03), but no changes in EE, epinephrine, dopamine, or HrV were observed. CONCLUSIONS: Metreleptin initiation decreased EE in patients with lipodystrophy, but no changes were observed after metreleptin withdrawal. Thyroid hormone was higher on metreleptin in both initiation and withdrawal cohorts. Decreased EE after metreleptin in lipodystrophy may result from reductions in energy-requiring metabolic processes that counteract increases in EE via adipose tissue-specific neuroendocrine and adrenergic signaling.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Grover A, Quaye E, Brychta RJ, et al. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2021. PMID: 33890058. doi:10.1210/clinem/dgab269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。